Escher is an independent, international research platform, with a pan-European focus. Escher builds on the results and track-record of the TI Pharma's Escher FES project. Today, Escher is TI Pharma's multi-stakeholder platform for research in regulatory and HTA topics to advance the development of socially valuable medicines.

A more efficient and effective regulatory system can help to better address medical needs by speeding up the development of innovative medicines and medical technology, while assuring safety and contributing to a better management of public expenditures on healthcare. Escher focuses on four research topics:

  • Evidence generation methods and evidence requirements
  • Scientific dialogue and stakeholder interaction
  • Decision-making process and benefit-risk analysis
  • Health technology assessment and societal impact evaluation

Currently, Escher is working on a project called "Improving the EU system for marketing authorization: Reviewing regulatory deficiencies and inefficiencies". It aims to:

  • Identify areas for potential improvement within the EU regulatory system that will positively affect innovative research and development, and the development of products that ad­dress medical need/priority medicines.
  • Generate evidence on the underlying problems with the regulatory system to help inform the agenda for policymaking at the European and national level.

Project partners:

  • Utrecht University
  • EFPIA
  • AESGP
  • Exon

More information can be found on the Escher website.

“TI Pharma's partnerships result in a synergy that really drives the science further than the individual parties could achieve working alone.”

Jan Raaijmakers
Past VP External Scientific Collaborations GSK Europe
Chair TI Pharma Board of Directors

Share this page: